Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.52 |
| ▸ | BTK | Q06187 | 16/20 | 0.51 |
| ▸ | JAK3 | P52333 | 15/20 | 0.51 |
| ▸ | BMX | P51813 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018864 | 0.95 | BTK (0.54) | SYKBTKJAK3BMXPTK2 | |
| SCHEMBL2122034 | 0.91 | JAK3 (0.63) | SYKBTKJAK3ITK | |
| SCHEMBL10127669 | 0.91 | SYK (0.54) | SYKBTKJAK3PTK2 | |
| SCHEMBL20715902 | 0.84 | JAK3 (0.60) | BTKJAK3ITK | |
| SCHEMBL19928464 | 0.83 | JAK3 (0.61) | BTKJAK3ITK | |
| SCHEMBL1706088 | 0.82 | SYK (0.56) | SYKBTKJAK3PTK2 | |
| SCHEMBL23258743 | 0.81 | JAK3 (0.43) | SYKBTKJAK3BMXPTK2 | |
| SCHEMBL10127678 | 0.81 | JAK3 (0.58) | BTKJAK3ITK | |
| SCHEMBL10127687 | 0.80 | JAK3 (0.52) | BTKJAK3BMXPTK2ITK | |
| SCHEMBL1223740 | 0.78 | SYK (0.60) | SYKBTKJAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-07 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | SYK 542/4885BTK 84/4885JAK3 37/4885 |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | EGFR, ERBB2, ERBB4 | SYK 542/4885BTK 84/4885JAK3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.